Refractory anti-viral resistant CMV retinitis in an immunological nonresponder person living with HIV

Int J Infect Dis. 2024 Nov:148:107229. doi: 10.1016/j.ijid.2024.107229. Epub 2024 Sep 1.

Abstract

Cytomegalovirus (CMV) retinitis caused by drug-resistant viruses poses a major challenge in immunocompromised patients. We present the case of a patient living with HIV with persistently low CD4+ T cells count despite effective antiretroviral therapy, who experienced multiple episodes of CMV retinitis associated with iterative acquisition of resistance. The failure of ganciclovir and foscarnet treatments led us to implement a combined therapy of intravenous cidofovir, high-dose ganciclovir, and anti-CMV immunoglobulin as well as intravitreal injections of ganciclovir. This triple therapy was successful but resulted in significant myelotoxicity. Furthermore, the relapse of CMV retinitis and/or CMV viremia with each therapeutic de-escalation reflects the high level of immunodeficiency in our patient, despite sustained control of HIV viremia for several months. This case report highlights the need for a particular management of CMV infection in patients living with HIV who are immunological nonresponders.

Keywords: CMV retinitis; Drug resistant cytomegalovirus; HIV; HIV immunological non responder.

Publication types

  • Case Reports

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / immunology
  • Adult
  • Antiviral Agents* / administration & dosage
  • Antiviral Agents* / therapeutic use
  • CD4 Lymphocyte Count
  • Cidofovir / therapeutic use
  • Cytomegalovirus / immunology
  • Cytomegalovirus Retinitis* / drug therapy
  • Cytomegalovirus Retinitis* / immunology
  • Drug Resistance, Viral*
  • Drug Therapy, Combination
  • Ganciclovir* / administration & dosage
  • Ganciclovir* / therapeutic use
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • HIV Infections* / immunology
  • HIV Infections* / virology
  • Humans
  • Immunocompromised Host
  • Male

Substances

  • Antiviral Agents
  • Ganciclovir
  • Cidofovir